Kennedy Ferruggia, Associate Editor

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

This week's episode tracks the growing nationwide cyclosporiasis outbreak and its link to lettuce, a new Utah pilot using artificial intelligence to authorize prescription refills, and FDA approvals in Alzheimer disease, precision oncology, and metastatic breast cancer.

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

Beckley Retreats CEO Neil Markey discusses how the recent executive order on psychedelic therapies for veterans could reshape access to ibogaine and other investigational treatments.

This week's episode covers a multistate rise in cyclosporiasis infections, insights from a Yale psychiatrist on safety monitoring for psychedelic therapies, and a wave of FDA approvals spanning nephrology, gene therapy, and cell therapy—plus a major expansion of the NIH's All of Us Research Program.

A study finds low-income and minority families are likely among those experiencing consequences from reduced measles, mumps, rubella, and varicella (MMRV) vaccine uptake amid the worst surge in US measles cases in decades.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

The authors said these data support the safety of current coadministration practice.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Sandie Kueker, RPh, shares how advocacy and a strong medication synchronization program have helped her independent pharmacies expand clinical services and better serve rural communities.

Emily Flaugher discusses how Health Mart Atlas tools and emerging legislative momentum are helping independent pharmacies navigate reimbursement challenges and unlock new revenue opportunities.

Crystal Lennartz, PharmD, MBA, discusses independent pharmacy resilience, recent industry recognitions, and new tools announced at McKesson ideaShare 2026 to support pharmacy growth and transparency.

Chris Van Norman discusses how technology, automation, and dedicated frontline teams keep the company's supply chain resilient and patient-focused.

Nancy Lyons, vice president and chief pharmacy officer at Health Mart, explains how McKesson Amplify and pharmacist-told patient care stories are driving advocacy wins for independent pharmacies at the state and federal levels.

Niki Shah, MHSA, MBA, CCHW, discusses how Project Oasis, a new diabetic retinopathy screening pilot, and the company's Community Health Worker scholarship program are working together to reduce barriers to care in under-resourced communities

FDA approval expands Breztri Aerosphere from COPD to asthma, offering single-inhaler triple therapy for adults and pediatric patients 12+.

The findings add to a growing body of evidence supporting metformin's role as a preventive strategy against postacute sequelae of COVID-19.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

At ACTHIV 2026, Jaimee Colvin, MSN, APRN, FNP-C, outlined how provider knowledge gaps, entrenched stigma, and a lack of culturally representative outreach continue to drive the PrEP disparity among cisgender Black and Brown women.

Jaimee Colvin, MSN, APRN, FNP-C, outlines the intentional, community-rooted, and representation-driven infrastructure required to scale PrEP access for cisgender women nationally.

This week's episode covers the first-ever joint guidelines for cardiovascular-kidney-metabolic syndrome, key highlights from ASCO 2026 and ADA 2026, and new FDA approvals in diabetes, infectious diseases, and pain management.